MedTrace Logo

Study of AT-527 in Healthy and HCV-Infected Subjects

NCT03219957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-02-18

No results posted yet for this study

Summary

This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.

Conditions

  • Chronic Hepatitis C
  • Hepatitis C
  • Hepatitis C, Chronic

Interventions

DRUG

AT-527

Ascending doses of AT-527 administered orally.

OTHER

Placebo Comparator

Matching placebo

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Xiao-Jian Zhou, PhD · Atea Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-06
Primary Completion
2018-06-20
Completion
2018-06-20

Countries

  • Belgium
  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219957 on ClinicalTrials.gov